Literature DB >> 26784579

The Effects of AS160 Modulation on Fatty Acid Transporters Expression and Lipid Profile in L6 Myotubes.

Agnieszka Mikłosz1, Bartłomiej Łukaszuk, Małgorzata Żendzian-Piotrowska, Krzysztof Kurek, Adrian Chabowski.   

Abstract

BACKGROUND/AIMS: AS160 is a key intracellular regulator of energy utilization in cells. It was shown to regulate GLUT4 translocation from intracellular depots to the plasma membrane, with subsequent changes in facilitated glucose uptake into the skeletal muscles. Similarly, also free fatty acids (FFAs) transmembrane transport seems to be largely protein-mediated. Therefore, the objective of this study was to examine the effects of moderate AS160 depletion (-82% mRNA, -25% of protein content) on the expression of fatty acid transporters and subsequent changes in lipid profile in L6 myotubes.
RESULTS: Surprisingly, moderate down regulation of AS160 expression was followed by increased AS160 phosphorylation (∼40%). These resulted in a greater expression of fatty acid transporters, namely FABPpm and FAT/CD36, with subsequently increased FAs cellular influx. No changes in the expression of FATP1 and 4 were noticed. Accordingly, we have observed a reduction in total TAG content. This was mainly caused by a significant changes in TAG fatty acids composition favouring a decrease in the amount of palmitic and stearic fatty acid moieties. In contrast, our experimental intervention led to distinctively increased total content of DAG and PL, but concomitantly decreased the content of all measured sphingolipids, e.g. SFA, SA1P, CER, SFO and S1P, in the AS160 knockdown group.
CONCLUSIONS: Modulation of AS160 level and activity led to significant increase in the concentration of DAG and PL, which was associated with changes in FAs composition and expression of fatty acid transporters. Interestingly, the intervention also simultaneously decreased the content of sphingolipids.
© 2016 The Author(s) Published by S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26784579     DOI: 10.1159/000438628

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  6 in total

1.  Changes in the Diaphragm Lipid Content after Administration of Streptozotocin and High-Fat Diet Regime.

Authors:  Bartlomiej Lukaszuk; Agnieszka Miklosz; Malgorzata Zendzian-Piotrowska; Beata Wojcik; Jan Gorski; Adrian Chabowski
Journal:  J Diabetes Res       Date:  2017-11-06       Impact factor: 4.011

2.  Metabolic Syndrome is Associated with Ceramide Accumulation in Visceral Adipose Tissue of Women with Morbid Obesity.

Authors:  Barbara Choromańska; Piotr Myśliwiec; Hady Razak Hady; Jacek Dadan; Hanna Myśliwiec; Adrian Chabowski; Agnieszka Mikłosz
Journal:  Obesity (Silver Spring)       Date:  2019-02-05       Impact factor: 5.002

3.  Dose- and time-dependent alterations in lipid metabolism after pharmacological PGC-1α activation in L6 myotubes.

Authors:  Elżbieta Supruniuk; Agnieszka Mikłosz; Adrian Chabowski; Bartłomiej Łukaszuk
Journal:  J Cell Physiol       Date:  2018-12-06       Impact factor: 6.384

4.  Pyrroloquinoline Quinone Modifies Lipid Profile, but Not Insulin Sensitivity, of Palmitic Acid-Treated L6 Myotubes.

Authors:  Elżbieta Supruniuk; Agnieszka Mikłosz; Adrian Chabowski
Journal:  Int J Mol Sci       Date:  2020-11-08       Impact factor: 5.923

5.  Challenging of AS160/TBC1D4 Alters Intracellular Lipid milieu in L6 Myotubes Incubated With Palmitate.

Authors:  Agnieszka Mikłosz; Bartłomiej Łukaszuk; Małgorzata Żendzian-Piotrowska; Justyna Brańska-Januszewska; Halina Ostrowska; Adrian Chabowski
Journal:  J Cell Physiol       Date:  2017-03-31       Impact factor: 6.384

6.  The Gene and Protein Expression of the Main Components of the Lipolytic System in Human Myocardium and Heart Perivascular Adipose Tissue. Effect of Coronary Atherosclerosis.

Authors:  Małgorzata Knapp; Jan Górski; Janina Lewkowicz; Anna Lisowska; Monika Gil; Beata Wójcik; Tomasz Hirnle; Adrian Chabowski; Agnieszka Mikłosz
Journal:  Int J Mol Sci       Date:  2020-01-22       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.